Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -865.5%
Operating margin was -865.5% in Q1 FY2026, down 268.0 pp from a year earlier. On a trailing-twelve-month basis it was -575.4%, down 233.3 pp year over year. Over 3 fiscal years it narrowed by 368.3 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 9 analysts of -560.2% for the fiscal year ending Dec 2026, down from -521.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -865.5%-339.0 pp QoQ
- Last fiscal yearDec 2025
- -521.0%-251.5 pp YoY
- LTMMar 2026
- -575.4%-233.3 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -521.0%
- Year-over-year change
- -251.5pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -521.0% | -251.5pp |
| FY2024 | 2024-12-31 | -269.6% | -128.6pp |
| FY2023 | 2023-12-31 | -141.0% | +11.8pp |
| FY2022 | 2022-12-31 | -152.7% | +26.6pp |
| FY2021 | 2021-12-31 | -179.3% | — |
Operating Margin vs competitors
How OCUL compares with its peers on the latest reported figures
- OCUL's LTM Mar 2026 operating margin of -575.4% is the 5th highest of the 9 companies compared; the peer median is -748.5%.
- Its year-over-year change of -233.3 pp is the 7th highest of 8, against a peer median of +8.3 pp.
- Over three fiscal years its change of -368.3 pp compares with a peer median of +5.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 10.5% | +8.3 pp | +12.0 pp | |
| LTM Jun 2026 | 7.1% | +5.5 pp | -1.8 pp | |
| LTM Apr 2026 | -1.7% | +22.5 pp | -34.6 pp | |
| LTM Jun 2026 | -13.1% | +9.2 pp | +12.0 pp | |
| LTM Mar 2026 | -575.4% | -233.3 pp | -368.3 pp | |
| LTM Mar 2026 | -1483.9% | -222.4 pp | +2154.3 pp | |
| LTM Mar 2026 | -3700.9% | -3412.9 pp | -535.3 pp | |
| LTM Mar 2026 | -16741.0% | — | — | |
| LTM Mar 2026 | -18182.8% | +26748.2 pp | — | |
| FY2025 | — | — | — | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding OCUL) | -748.5% | +8.3 pp | +5.1 pp | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M |
| Cost of Revenue | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | 39.12M | 46.95M | 53.16M | 58.1M | 45.25M |
| Gross Margin | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Research & Development | 50.08M | 53.46M | 61.06M | 127.64M | 197.1M |
| Selling, General & Admin | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M |
| Operating Expenses | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| EBITDA | 2.54M | (61.91M) | (66.42M) | (176.14M) | (249.78M) |
| EBITDA Margin | 5.8% | -120.2% | -113.6% | -276.4% | -482.0% |
| Operating Income | (78.04M) | (78.65M) | (82.38M) | (171.78M) | (270.02M) |
| Operating Margin | -179.3% | -152.7% | -141.0% | -269.6% | -521.0% |
| Interest Income | 33K | 798K | 3.98M | 20.28M | 18.36M |
| Interest Expense | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M |
| Other Income / Expenses | 71.48M | 7.62M | 1.65M | (21.73M) | 4.08M |
| Income Before Tax | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Pre-Tax Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Net Margin | -15.1% | -138.0% | -138.1% | -303.7% | -513.2% |
| EPS (Basic) | (1.05) | (1.04) | (1.09) | (1.22) | (1.42) |
| EPS (Diluted) | (0.98) | (0.97) | (1.02) | (1.22) | (1.42) |
| Weighted Avg Shares | 76.39M | 76.88M | 79.83M | 158.27M | 187.24M |
| Weighted Avg Shares (Diluted) | 82.16M | 82.64M | 85.6M | 158.27M | 187.24M |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.